Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Revenue (2019 - 2025)

Burning Rock Biotech has reported Revenue over the past 7 years, most recently at $18.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 4.62% year-over-year to $18.1 million; the TTM value through Dec 2025 reached $75.6 million, up 5.56%, while the annual FY2025 figure was $77.2 million, 9.18% up from the prior year.
  • Revenue for Q4 2025 was $18.1 million at Burning Rock Biotech, down from $18.5 million in the prior quarter.
  • Over five years, Revenue peaked at $23.1 million in Q4 2021 and troughed at $16.3 million in Q1 2021.
  • A 5-year average of $19.2 million and a median of $19.1 million in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: skyrocketed 68.69% in 2021 and later fell 19.56% in 2023.
  • Year by year, Revenue stood at $23.1 million in 2021, then dropped by 10.81% to $20.6 million in 2022, then fell by 17.3% to $17.1 million in 2023, then rose by 1.24% to $17.3 million in 2024, then rose by 4.62% to $18.1 million in 2025.
  • Business Quant data shows Revenue for BNR at $18.1 million in Q4 2025, $18.5 million in Q3 2025, and $20.7 million in Q2 2025.